Maze Therapeutics (NASDAQ:MAZE) CEO Sells $103,818.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 3,993 shares of Maze Therapeutics stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $26.00, for a total transaction of $103,818.00. Following the transaction, the chief executive officer directly owned 25,930 shares of the company’s stock, valued at $674,180. This represents a 13.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Price Performance

Maze Therapeutics stock traded up $0.19 during trading hours on Wednesday, hitting $26.60. 657,539 shares of the stock were exchanged, compared to its average volume of 688,291. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88. The stock has a market capitalization of $1.47 billion, a P/E ratio of -10.51 and a beta of 2.27. Maze Therapeutics, Inc. has a 12 month low of $9.83 and a 12 month high of $53.65. The business’s 50-day moving average is $25.67 and its two-hundred day moving average is $36.25.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. Equities research analysts expect that Maze Therapeutics, Inc. will post -2.76 EPS for the current fiscal year.

Institutional Investors Weigh In On Maze Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC boosted its holdings in Maze Therapeutics by 318.0% in the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock valued at $130,197,000 after acquiring an additional 2,390,713 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Maze Therapeutics by 218.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after purchasing an additional 915,342 shares during the last quarter. Marshall Wace LLP grew its position in shares of Maze Therapeutics by 3,868.5% during the 3rd quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock worth $20,166,000 after buying an additional 758,104 shares during the period. Caligan Partners LP acquired a new stake in shares of Maze Therapeutics during the 4th quarter worth approximately $22,794,000. Finally, ArrowMark Colorado Holdings LLC bought a new stake in shares of Maze Therapeutics during the third quarter worth approximately $14,135,000.

Analysts Set New Price Targets

Several brokerages have recently commented on MAZE. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. BTIG Research reaffirmed a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, March 25th. Mizuho upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. Wedbush increased their price objective on shares of Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a report on Monday, March 16th. Finally, Guggenheim raised their price objective on shares of Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.